Strongly


An expression of the live unlimited spirit, stories and voices of the MDA community

FDA Extends Decision Deadline Date for Eteplirsen to May 26, 2016

Background: Sarepta Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has extended the decision goal date for eteplirsen by a standard extension period of three months. The new date by which the FDA must make a decision about whether to approve eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) is May 26, 2016. . . .

Read More

FDA Issues Response to BioMarin’s DMD Treatment

Press Release: FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Summary: BioMarin reported today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) indicating that the review cycle for the company’s New Drug Application for drisapersen (Kyndrisa) to treat DMD is . . .

Read More

Phase 3 Trial for Experimental Drug Tirasemtiv Currently Recruiting Participants with ALS

Researchers are looking for people with amyotrophic lateral sclerosis (ALS) to participate in the phase 3 VITALITY-ALS clinical trial, sponsored by Cytokinetics, to test the experimental drug tirasemtiv. Tirasemtiv is a skeletal muscle activator that is designed to increase the sensitivity of muscle fibers to calcium, which should cause these fibers to contract even if . . .

Read More

Eli Lilly Provides Update on Phase 3 Tadalafil Trial for DMD

Please read the message below from Eli Lilly regarding the results of their phase 3 trial in Duchenne muscular dystrophy (DMD): Update on Phase 3 Tadalafil Trial We are writing to share disappointing news about our Phase 3 study of tadalafil in approximately 330 patients with Duchenne muscular dystrophy (DMD). We recently completed analysis of . . .

Read More

Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on DMD Drug

CAMBRIDGE, MA, and CHICAGO, IL, February 5, 2016 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, and the Muscular Dystrophy Association (MDA), today announced a collaboration to support the Part B portion of the MoveDMD clinical trial of CAT-1004, a novel product candidate for the treatment . . .

Read More

On Growing Up with MDA and Helping MDA Grow Up

Like most recent college graduates preparing to enter the “real world,” I was in the throes of the inevitable what-the-heck-am-I-going-to-do-with-my-life panic when an unexpected call set me on a new path. In accepting the offer to become the first adult MDA National Goodwill Ambassador, I could stop speculating about what my next life journey will . . .

Read More

Relive the Excitement of January 29

Jump to Storify Jump to Video The reviews are in! Last week’s event in New York City was a major hit! Check out some of these reactions from MDA’s Facebook followers: “I really enjoyed watching the live stream today of the event, As a person who has MD I want to Thank all those who . . .

Read More

Jordan Smith’s Emotional Performance of “The Climb”

Jordan Smith, winner of the ninth season of The Voice singing competition on NBC, closed out our January 29 event in New York with an emotional rendition of Miley Cyrus’s “The Climb.” The song’s lyrics — about obstacles and overcoming them despite great odds — resonated with our audience of families and supporters. Jordan, who once told a . . .

Read More

What is the MDCC?

        If you are interested in muscular dystrophy research, you need to know about the MDCC…  What is the MDCC? You may have previously come across the acronym “MDCC” posted on MDA’s website or social media pages. MDCC stands for the Muscular Dystrophy Coordinating Committee. The Committee was established under the MD-CARE . . .

Read More